Every 21 seconds someone in the USA calls Poison Control because of a medication error. A new study from the Center for Injury Research and Policy and the Central Ohio Poison Center at Nationwide Children’s Hospital (Columbus, Ohio) analysed calls to Poison Control Centers across the country over a 13-year period about exposures to medication errors which resulted in serious medical outcomes. These exposures, which occurred outside of health care facilities, primarily in the home, affected individuals of all ages and were associated with a wide variety of medications. Cardiovascular drugs were one of the most frequently-associated medications.
A stent coated with sildenafil (Viagra, Pfizer, and others) may someday help prevent arteries from becoming narrow or blocked again, according to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences 2017 Scientific Sessions (BCVS; 10–13 July, Portland, USA).
Radical changes to our health care system that take into account the unique needs of women, including minority populations, are needed to ensure women are receiving the same high-quality care that men receive, according to a review paper published today in the Journal of the American College of Cardiology and written by members of the American College of Cardiology Cardiovascular Disease in Women Committee.
Medtronic has announced that the FDA has approved the company’s self-expanding transcatheter aortic valve implantation (TAVI) system CoreValve Evolut for the management of intermediate-risk patients with aortic stenosis. The approval follows the presentation of the SURTAVI study at the 2017 American College of Cardiology Scientific Session (17–19 March, Washington, DC, USA).
Jonathan Afilalo (Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Canada) and others report in the Journal of American College of Cardiology that the Essential Frailty Toolset (EFT) outperforms other scales when assessing frailty in patients with aortic stenosis, adding that the toolset is, therefore, “recommended” for this setting.
Medtronic will release the Resolute Onyx coronary stent system in Japan. According to a press release, the device offers superior deliverability to that of its predecessor, Resolute Integrity.
Edwards Lifesciences has FDA approval for its Inspiris Resilia surgical aortic valve, which a press release reports is the first in a new class of resilient heart valves. The press release adds that the valve features Resilia tissue, which is designed to deliver the combination of enhanced anticalcification properties, improved sustained haemodynamic performance and dry storage.
A private cardiology clinic in Berlin, Germany, headed by Niels Jacobsohn has placed the first order in the important German market for Acarix’ CADScor system for non-invasive, non-radiation acoustic detection of coronary artery disease.
Researchers at Georgia Institute of Technology and the Piedmont Heart Institute (both Atlanta, USA) are using standard medical imaging and new 3-D printing technologies to create patient-specific heart valve models that mimic the physiological qualities of the real valves. Their aim is to improve the success rate of transcatheter aortic valve implantation (TAVI) by picking the right prosthetic and avoiding paravalvular leakage.
The UK’s Information Commissioner’s Office (ICO) has found that the Royal Free NHS Foundation Trust (London, UK) did not adhere to the UK’s Data Protection Act when it provided patient details to Google DeepMind. The Trust, a press release reports, provided personal data for around 1.6 million patients as part of a trial to test an alert, diagnosis and detection system for acute kidney injury.
LifeTech, at the 2017 Congenital and Structural Intervention Congress (CSI; 28 June—1 July, Frankfurt, Germany), announced the launch of a three-year global postmarket surveillance study for the LAmbre left atrial appendage (LAA) closure system. A press release reports that the aim is to enrol more than 500 patients from about 30 clinical centres in Europe, Asia and South America.
Breast implants may disrupt an electrocardiogram (ECG) and could result in a false heart attack diagnosis, according to research presented at EHRA EUROPACE – CARDIOSTIM 2017.
A new study from the Women in Innovation Initiative and Drug-Eluting Stents (WIN-DES) collaborative has found that the use of new-generation drug-eluting stents is associated with durable and consistent benefits, compared with early-generation stents, in women with acute myocardial infarction. Previous findings from the collaborative have shown that new-generation drug-eluting stents provide benefits for women undergoing percutaneous coronary intervention (PCI).
Ravi S Hira (Section of Cardiology, University of Washington, Seattle, USA) and others report in JAMA Cardiology that 9.5% of US transcatheter aortic valve implantation (TAVI) procedures are performed off-label. However, they note that the rate of one-year mortality associated with these procedures is similar to that of on-label procedures.
A study published in the Journal of Interventional Cardiology indicates that the use of the Impella 2.5 heart pump (Abiomed) is associated with a significant survival benefit in patients with acute myocardial infarction and cardiogenic shock when inserted prior to percutaneous coronary intervention (PCI).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos